Uso de pentoxifilina en pacientes pediátricos con nefropatía lúpica grado IV (OMS) multitratados

Revista Alergia Mexico

Volumn 47, Issue 3, 2000, Pages 109-114

  De García, María Jesús Vázquez ^a,d   Camaño, María Eugenia Vargas ^b   Carmona, René Olalde ^c  

^a Departamento de Alergia   (Mexico)

^b Inmunologia Clinica   (Mexico)

^c Jefe Nefrologia Pediat CMN

^d Los Reyes Culhuacan Del Iztapalapa   (Mexico)

Author keywords

Lupic nephropaty; Pentoxfillyne

Indexed keywords

PENTOXIFYLLINE;

ADOLESCENT; ARTICLE; CHILD; FEMALE; HEMATURIA; HUMAN; INFANT; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 0038689542     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. a edición. Editorial Churchill Livingstone. 1996. 683-701. Nueva York. E.U.A.
2. a edición. 1984 50-56. Editorial DOYMA. España.
3. Shayakul Ch, Ong-aj-yooth L, Chirawong P, Nimmannit S, Pirichatikanod P and cols. Lupus nephritis in Thailand: clinicophatologic findings and outcome in 569 patients. Am J of Kidney Dis 1995; 66,2: 300-307.
4. De Vault G, Kohan D E, Nelson E W, and Holman J M. The effects of oral pentoxifylline on the citokine release syndrome during inductive OKT3. Transplant 1994; 57,4: 532-540.
5. Seedat Y K, Parag K B, Ramsarop R. Sistemic lupus erytemoatosus and renal involment. Nephron 1994; 66:426-430.
6. Yasui K, Ohta K, Kobayashi M, Aizawa T. Succesful treatment of behcet disease with pentoxifylline. Ann Int Med 1996; 87, 2: 891-893.
7. Kano Y, Hirayama M, Shiohara T. Succesfful treatment of Shamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36: 827-830.
8. Kiley P D, Gillespie K M, Oliveira D B. Oxipentifylline inhibits tumor necrosis factor alpha m RNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995; 25: 2899-2906.
9. Elbim C, Lefebure M, Hakim J, Gougerot-Pocidalo M A. Effects of pentoxifylline on human polymorphonuclear neutrophil responses to TNF in whole blood. Eur Cytok Network 1995; 6: 113-120.
10. Hooler E, Moler A, Kempeni J, Liesnfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alfa precede major complications of bone marrow transplantation. Blood 1990; 75, 4: 1011-1016.
11. Bergese S, Pelletier R, Ohye R, Vallera D and cols. Treatment of mice with anti CD3m Ab induces endothelial vascular cell adhesion molecule-1 expression. Transplant 1994; 57, 5: 711-717.
12. Mandi Y, Farkas G, Ocsovszky L, Nagy Z. Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Res Exp Med 1995; 195:: 297-307.
13. Alegre M L, Gastaldello K, Abramowicz D, Kinnaeret P, Vereestraeten P et al. Evidence that pentoxifylline reduces anti CD3 monoclonal antibody-induces cytokine release syndrome. Transplant 1991; 52, 4: 674-679.
14. Bemelmans M, Abramowicz, Gouma D J, Goldman M and Buurman W. In vivo T cell activation by anti CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, metilprednisolona, anti-TNF and anti IFN-y antibodies. J of Immunol 1994; 153: 499-506.
15. Tsujino A A, Nakamura Y, Shirabe S, Furuya T. Pentoxifylline down-regulates adhesion molecule expression and inflamatory cytokine production in cultured peripheral blood mononuclear cells from patiens with HTLV-1 associated myelopathy. J Neuroimmunol 1997; 73: 191-196.
16. Neuner P, Klosner G, PourmojibM, Knober R and Schwarz T. Pentoxifylline in vivo and in vitro down-regulates the expression of the intracellular adhesion molecule-1 in monocytes. Immunol 1997; 90: 435-439.
17. Tilg H, Eibl B, Pichl M, Gachter A, Herold M. Immune response modulation by pentoxifylline in vitro. Transplant 1993; 56,1: 196-201.
18. Boldt J, Muller M, Hessen M. Influence of different volume therapies and pentoxifylline infussion on circulating soluble adhesion molecules in critically ill patients. Critical Care Med 1996; 24: 385-391.
19. Bianco J A, Appelabum F R, Nemunaitis J, Almgre J. Phase I-II trial of pentoxifylline for prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78,5: 1205-1211.